Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019)

References

• Sui X, Church TS, Meriwether RA, et al. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845–852.
   PubMed Web of Science ®Google Scholar
• Lee JM, Kim HC, Cho HM, et al. Association between serum uric acid level and metabolic syndrome. J Prev Med Public Health. 2012;45:181–187.
   PubMedGoogle Scholar
• Zoccali C, Mallamaci F. Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep. 2013;15:531–537.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649–662.
   PubMed Web of Science ®Google Scholar
• Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1470–1476.
   PubMed Web of Science ®Google Scholar
• Cristóbal-García M, García-Arroyo FE, Tapia E, et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev. 2015;2015:535686.
   PubMed Web of Science ®Google Scholar
• Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14.
   PubMed Web of Science ®Google Scholar
• Hyndman D, Liu S, Miner JN. Urate handling in the human body. Curr Rheumatol Rep. 2016;18:34.
   PubMed Web of Science ®Google Scholar
• Tan PK, Farrar JE, Gaucher EA, et al. Coevolution of URAT1 and uricase during primate evolution: implications for serum urate homeostasis and gout. Mol Biol Evol. 2016;33:2193–2200.
   PubMed Web of Science ®Google Scholar
• Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet. 2009;18:R177–84.
   PubMed Web of Science ®Google Scholar
• So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120:1791–1799.
   PubMed Web of Science ®Google Scholar
• Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447–452.
   PubMed Web of Science ®Google Scholar
• Stocker SL, Graham GG, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38:904–910.
   PubMed Web of Science ®Google Scholar
• Underwood M. Diagnosis and management of gout. BMJ. 2006;332:1315–1319.
   PubMed Web of Science ®Google Scholar
• Babany G, Larrey D, Pessayre D, et al. Chronic active hepatitis caused by benzarone. J Hepatol. 1987;5:332–335.
   PubMed Web of Science ®Google Scholar
• Miner JN, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214.
   PubMed Web of Science ®Google Scholar
• Pan Y, Kong LD. Urate transporter URAT1 inhibitors: a patent review (2012-2015). Expert Opin Ther Pat. 2016;26:1129–1138.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Lesinurad: first global approval. Drugs. 2016;76:509–516.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;53:2167–2174.
   PubMed Web of Science ®Google Scholar
• Zhao G, Liu W, Shang Q, et al. Preparation of carboxylic acid URAT1 inhibitors. WO2016173503A1. 2016.
   Google Scholar
• Liu C, Chen H, Shang Q, et al. 1-(1,2,4-Triazol-1-ylmethyl)naphthalene derivatives as URAT1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of gout and hyperuricemia. CN108658879A. 2018.
   Google Scholar
• Zhao G, Tian H, Shang Q, et al. Triazole n-propionic acid-type URAT1 inhibitor, preparing method thereof, and application thereof in treating hyperuricemia and gout. CN105820130A. 2016.
   Google Scholar
• Feng W, Feng X, Huang Z, et al. Preparation of 2-[[5-bromo-4-[4-(fluorocyclopropyl)naphthalen-1-yl]-4H-1,2,4-triazol-3-yl]thio]acetic acid compounds useful as urate transporter 1 inhibitors. CN107176930A. 2017.
   Google Scholar
• Wang J, Zhang Y, Zhu W, et al. Preparation of (triazolyl)thiophene derivatives useful as URAT1 inhibitors. WO2017202291A1. 2017.
   Google Scholar
• Zuo X, Huo Z, Kang D, et al. Current insights into anti-HIV drug discovery and development: A review of recent patent literature (2014-2017). Expert Opin Ther Pat. 2018;28:299–316.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang W, Hu Z, et al. Benzimidazole derivatives, preparation method therefor, and applications thereof. WO2017107864A1. 2017.
   Google Scholar
• Chen L, Xing X, Liu Y, et al. Preparation of the URAT1 inhibitor for treating hyperuricemia and gout. CN107814795A. 2018.
   Google Scholar
• Zhao G, Cai W, Shang Q, et al. Preparation of 3-bromo-4-(naphthalen-1-yl)-5-[(1H-tetrazol-5-yl)methylthio]-4H-1,2,4-tetrazole derivs. useful as URAT1 inhibitors for the treatment fo hyperuricemia and gout. CN106032377A. 2016.
   Google Scholar
• Zhang Y. Preparation of halogenated triazole sulfonyl malonic acid compound and their application as uric acid transporter I inhibitor. CN104356078A. 2015.
   Google Scholar
• Zhang Y. Preparation of triazole derivatives for treatment of hyperuricemia and gout. CN104370843A. 2015.
   Google Scholar
• Peng J, Hu Q, Gu C, et al. Discovery of potent and orally bioavailable inhibitors of human uric acid transporter 1 (hURAT1) and binding mode prediction using homology model. Bioorg Med Chem Lett. 2016;26:277–282.
   PubMed Web of Science ®Google Scholar
• Miner JN, Tan P. RDEA3170, a novel, high affinity URAT1 inhibitor binds to a central domain within URAT1. Ann Rheum Dis. 2013;71:446.
   Web of Science ®Google Scholar
• Shen Z, Gillen M, Miner JN, et al. pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Devel Ther. 2017;11:2077–2086.
   PubMed Web of Science ®Google Scholar
• Endo T, Kobayashi K, Tanaka H, et al. Aromatic or heteroaromatic compd., its use for urate transporter 1 (URAT1) inhibitor, pharmaceutical compn., and treatment of gout or hyperuricemia, and screening method for URAT1 inhibitor. WO2016108282A1. 2016.
   Google Scholar
• Xu Z, Zhang N, Sun Q, et al. Preparation of condensed ring derivatives for treating hyperuricemia and related diseases. WO2016150255A1. 2016.
   Google Scholar
• Li T, Zhao X, Yu C, et al. Preparation of indolizine derivatives as URAT1 inhibitors. WO2017114352A1. 2017.
   Google Scholar
• Fan L, Du W, Li X, et al. Preparation of 4-thioquinoline derivatives useful as urate transporter 1 inhibitors. WO2017097182A1. 2017.
   Google Scholar
• Fan L, Du W, Xu K, et al. Heterocyclic compound and its preparation method. CN108659000A. 2018.
   Google Scholar
• Ahn SO, Ohtomo S, Kiyokawa J, et al. Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther. 2016;357:157–166.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Ashizawa N, Matsumoto K, et al. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor. J Pharm Pharmacol. 2016;68:76–83.
   PubMed Web of Science ®Google Scholar
• Shi D, Fu C, Cheng X 3-(4-Hydroxybenzoyl)benzofuran compounds as URAT1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of hyperuricemia or gout. CN106065010A. 2016.
   Google Scholar
• Yan S, Yeh L, Orr R. Methods comprising benzbromarone compounds for treating or preventing a symptom associated with gout or hyperuricemia. WO2018017368A1. 2018.
   Google Scholar
• Shi D, Fu C, Cheng, et al. URAT1 inhibitor, preparation and application. WO2018090921A1. 2018.
   Google Scholar
• Shi D, Zhou H, Zhu J, et al. Preparation of indazole derivatives useful as URAT1 inhibitors for the treatment of hyperuricemia, kidney disease and gout. CN108727267A. 2018.
   Google Scholar
• Shi D, Zhu J, Gu J, et al. Preparation of URAT1 inhibitors. CN108484600A. 2018.
   Google Scholar
• Roda A, Cerrè C, Manetta AC, et al. Synthesis and physicochemical, biological, and pharmacological properties of new bile acids amidated with cyclic amino acids. J Med Chem. 1996;39:2270–2276.
   PubMed Web of Science ®Google Scholar
• Breslin HJ, Lane BM, Ott GR, et al. Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.13,⁷.1⁹, 13]docosa-1(20), 3(22),4,6,9(21),10,12,16,18-nonaenemacrocycles. J Med Chem. 2012;55:449–464.
   PubMed Web of Science ®Google Scholar
• Chakravarty PK, Naylor EM, Chen A, et al. A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist. J Med Chem. 1994;37:4068–4072.
   PubMed Web of Science ®Google Scholar
• Pinard E, Alberati D, Borroni E, et al. of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett. 2008;18:5134–5139.
   PubMedGoogle Scholar
• Sturino CF, O’Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem. 2007;50:794–806.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–884.
   PubMed Web of Science ®Google Scholar
• Quesnel LB, Al-Najjar AR, Buddhavudhikrai P. Synergism between chlorhexidine and sulphadiazine. J Appl Bacteriol. 1978;45:397–405.
   PubMedGoogle Scholar
• Uchida T, Hayashi K, Kido H, et al. Diuretic action of the novel loop diuretic torasemide in the presence of angiotensin II or endothelin-1 in anaesthetized dogs. J Pharm Pharmacol. 1992;44:39–43.
   PubMed Web of Science ®Google Scholar
• Grell W, Hurnaus R, Griss G, et al. Repaglinide and related hypoglycemic benzoic acid derivatives. J Med Chem. 1998;41:5219–5246.
   PubMed Web of Science ®Google Scholar
• Colas B, Slama M, Masson H, et al. Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol. 2000;14:363–368.
   PubMed Web of Science ®Google Scholar
• Miyashita M, Matsumoto T, Matsukubo H, et al. Synthesis and antiulcer activity of N-substituted N’-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity. J Med Chem. 1992;35:2446–2451.
   PubMed Web of Science ®Google Scholar
• Fan L, Xu K, Chen K, et al. Sulfonamide compound as URAT1 inhibitor and its preparation. CN108863919A. 2018.
   Google Scholar
• Fan L, Du W, Li X, et al. Sulfonamide compound, preparation method thereof and application thereof as urate transporter inhibitor type drug. CN106831556A. 2017.
   Google Scholar
• Fan L, Li X, Chen Y, et al. Preparation of quinoline derivatives as uric acid salt transporter inhibitors. CN106831570A. 2017.
   Google Scholar
• Wang Y, Zheng G, Liu L, et al. Medical use of 2-trifluoromethylbenzenesulfonamide derivative. WO2019011176A1. 2019.
   Google Scholar
• Wang Y, Zheng G, Liu L, et al. Preparation of sulfanilamide derivatives for treatment of gout. CN108689987A. 2018.
   Google Scholar
• Azevedo VF, Buiar PG, Giovanella LH, et al. Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. 2014;2014:263720.
   PubMedGoogle Scholar
• Dua P, Gurrell R, Kirby S, et al. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clin Rheumatol. 2016;35:2045–2051.
   PubMed Web of Science ®Google Scholar
• Piwinski JJ, Larivee A, Siddiqui A, et al. Preparation of dihydropyrimidine carboxamide derivatives and their use for reducing uric acid levels. WO2018009615A1. 2018.
   Google Scholar
• Piwinski JJ, Buckle RN, Larivee A, et al. Preparation of bifunctional compounds and their use for reducing uric acid levels. WO2018005192A1. 2018.
   Google Scholar
• Warrell RP, Piwinski JJ Preparation of oxopyrimidinecarboxamides as bifunctional compounds and use for reducing uric acid levels. WO2016118611A1. 2016.
   Google Scholar